Sanofi: positive CHMP opinion for dengue vaccine
(CercleFinance.com) - Sanofi announces that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the application for a marketing authorisation of its dengue vaccine.
Disabling illness usually characterized by prolonged fever and severe joint pain, dengue fever can sometimes progress to life-threatening complications. According to the WHO, it threatens nearly half of the world's population in 128 countries.
The dengue vaccine has been evaluated in clinical trials that included over 40,000 people in 15 countries. The European Commission is expected to give its marketing authorisation in December.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Disabling illness usually characterized by prolonged fever and severe joint pain, dengue fever can sometimes progress to life-threatening complications. According to the WHO, it threatens nearly half of the world's population in 128 countries.
The dengue vaccine has been evaluated in clinical trials that included over 40,000 people in 15 countries. The European Commission is expected to give its marketing authorisation in December.
Copyright (c) 2018 CercleFinance.com. All rights reserved.